Xenadrine-EFX
This article was originally published in The Tan Sheet
Executive Summary
FTC is reviewing advertising for ephedra-free weight-loss product, previous marketer Cytodyne told the National Advertising Division of the Council of Better Business Bureaus in response to an inquiry, according to a recent NAD release. As a result, the firm declined to take part in NAD's request for substantiation of a number of claims including the statement that Xenadrine-EFX "was clinically tested against two leading ephedra-based thermogenic supplements and outperformed them for both the boosting of metabolism, and resulting caloric expenditure." Marketer of the supplement is now known as Nutraquest...
You may also be interested in...
Xenadrine
Respondent of NAD inquiry, marketer of Xenadrine EFX is Cytodyne LLC, not Cytodyne, as recently reported (1"The Tan Sheet" March 15, 2004, In Brief). The original Cytodyne licensed rights to its products to newly created entity Cytodyne LLC, a subsidiary of Phoenix Labs, in 2003 (2"The Tan Sheet" June 23, 2003, p. 13). The entity formerly known as Cytodyne is now called Nutraquest, which was not involved in the events related to the NAD inquiry...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.